Global Anti-Aging Drugs Market

Anti-Aging Drugs Comprehensive Study by Application (Skin and Hair, Skeletal and Muscles, Age Related Disorders, Others), Therapy (Homeopathic, Allopathic), Drug Class (Serums and Supplement, Antioxidants and Enzymes, Stem Cells, Drugs) Players and Region - Global Market Outlook to 2030

Anti-Aging Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Anti-Aging Drugs Market Scope
Anti-aging drugs are generally used to slow down or reverse the process of aging aiming to extend the healthy lifespan. It is the combination of advanced biotechnology and clinical preventing medicines which is used for prevention and treatment of age associated disorders and diseases. Further, many medical technologies are being developed in order to delay the aging process. Also, the advancements in medical science and rising health consciousness among people are the key factors boosting the market growth.

AttributesDetails
Study Period2018-2030
Base Year2023
Largest MarketNorth America
UnitValue (USD Million)
Key Companies ProfiledNu Skin Enterprises (United States), Novartis AG (Switzerland), BioTime Inc. (United States), ARK Skincare (United Kingdom), Elysium Health Inc. (United States), Estee Lauder Inc. (United States), DermaFix (South Africa), Bayer Pharma AG (Germany), La Roche-Posay (United States) and L’Oreal SA (France)
CAGR%


The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market in the near future. Players are anticipated to focus on the development of new compounds, which is likely to encourage the growth of the global market throughout the forecast period. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Anti-Aging Drugs market throughout the predicted period.

Nu Skin Enterprises (United States), Novartis AG (Switzerland), BioTime Inc. (United States), ARK Skincare (United Kingdom), Elysium Health Inc. (United States), Estee Lauder Inc. (United States), DermaFix (South Africa), Bayer Pharma AG (Germany), La Roche-Posay (United States) and L’Oreal SA (France) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Anti-Aging Drugs market by Type , by Application (Skin and Hair, Skeletal and Muscles, Age Related Disorders and Others) and Region with country level break-up.

On the basis of application, Skin and Hair segment is dominating the market in the year 2023 where as Age Related Disorders segment stood as second largest market.

On the basis of geography, the market of Anti-Aging Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Asia Pacific on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.

Market Leaders and their expansionary development strategies
On 20 Dec 2018, Novartis today announced an offer to acquire CellforCure from LFB. CellforCure, a French company, is one of the first and largest contract development and manufacturing organizations (CDMO) producing cell and gene therapies in Europe.
On 21 Dec 2018, Novartis today announced that it has completed the acquisition of Endocyte, Inc., a US-based biopharmaceutical company focused on developing radioligand and CAR-T therapies for cancer treatment.
Under the law, cosmetics must be safe when consumers use them according to product labeling, or the way in which the products are customarily used. But the law does not require cosmetics to be approved by FDA before they go on the market. Drugs, however, must have FDA approval for both safety and effectiveness before they go on the market. Similarly, medical devices must go through FDA’s clearance process.

Influencing Trend:
Primitive desire of people to remain young

Market Growth Drivers:
Rising awareness toward age related problems and increasing concerns about looks and appearance among people, Advancement in medical science and development of new anti-aging drugs and Growing aged population worldwide

Challenges:
Intense competition across the globe

Restraints:
Stringent regulations and definition ambiguity

Opportunities:
New advanced technologies and cellular understanding

Key Target Audience
Manufacturers of anti-aging drugs, Suppliers of anti-aging drugs components, Wholesalers, distributers and retailers of anti-aging drugs, Research and development companies, Hospitals & clinics and Academic institutes and universities

Report Objectives / Segmentation Covered

By Application
  • Skin and Hair
  • Skeletal and Muscles
  • Age Related Disorders
  • Others
By Therapy
  • Homeopathic
  • Allopathic

By Drug Class
  • Serums and Supplement
  • Antioxidants and Enzymes
  • Stem Cells
  • Drugs

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising awareness toward age related problems and increasing concerns about looks and appearance among people
      • 3.2.2. Advancement in medical science and development of new anti-aging drugs
      • 3.2.3. Growing aged population worldwide
    • 3.3. Market Challenges
      • 3.3.1. Intense competition across the globe
    • 3.4. Market Trends
      • 3.4.1. Primitive desire of people to remain young
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anti-Aging Drugs, by Application, Therapy, Drug Class and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Anti-Aging Drugs (Value)
      • 5.2.1. Global Anti-Aging Drugs by: Application (Value)
        • 5.2.1.1. Skin and Hair
        • 5.2.1.2. Skeletal and Muscles
        • 5.2.1.3. Age Related Disorders
        • 5.2.1.4. Others
      • 5.2.2. Global Anti-Aging Drugs by: Therapy (Value)
        • 5.2.2.1. Homeopathic
        • 5.2.2.2. Allopathic
      • 5.2.3. Global Anti-Aging Drugs Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Anti-Aging Drugs (Volume)
      • 5.3.1. Global Anti-Aging Drugs by: Application (Volume)
        • 5.3.1.1. Skin and Hair
        • 5.3.1.2. Skeletal and Muscles
        • 5.3.1.3. Age Related Disorders
        • 5.3.1.4. Others
      • 5.3.2. Global Anti-Aging Drugs by: Therapy (Volume)
        • 5.3.2.1. Homeopathic
        • 5.3.2.2. Allopathic
      • 5.3.3. Global Anti-Aging Drugs Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Anti-Aging Drugs (Price)
  • 6. Anti-Aging Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Nu Skin Enterprises (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BioTime Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. ARK Skincare (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Elysium Health Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Estee Lauder Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. DermaFix (South Africa)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer Pharma AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. La Roche-Posay (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. L’Oreal SA (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Anti-Aging Drugs Sale, by Application, Therapy, Drug Class and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Anti-Aging Drugs (Value)
      • 7.2.1. Global Anti-Aging Drugs by: Application (Value)
        • 7.2.1.1. Skin and Hair
        • 7.2.1.2. Skeletal and Muscles
        • 7.2.1.3. Age Related Disorders
        • 7.2.1.4. Others
      • 7.2.2. Global Anti-Aging Drugs by: Therapy (Value)
        • 7.2.2.1. Homeopathic
        • 7.2.2.2. Allopathic
      • 7.2.3. Global Anti-Aging Drugs Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Anti-Aging Drugs (Volume)
      • 7.3.1. Global Anti-Aging Drugs by: Application (Volume)
        • 7.3.1.1. Skin and Hair
        • 7.3.1.2. Skeletal and Muscles
        • 7.3.1.3. Age Related Disorders
        • 7.3.1.4. Others
      • 7.3.2. Global Anti-Aging Drugs by: Therapy (Volume)
        • 7.3.2.1. Homeopathic
        • 7.3.2.2. Allopathic
      • 7.3.3. Global Anti-Aging Drugs Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Anti-Aging Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anti-Aging Drugs: by Application(USD Million)
  • Table 2. Anti-Aging Drugs Skin and Hair , by Region USD Million (2018-2023)
  • Table 3. Anti-Aging Drugs Skeletal and Muscles , by Region USD Million (2018-2023)
  • Table 4. Anti-Aging Drugs Age Related Disorders , by Region USD Million (2018-2023)
  • Table 5. Anti-Aging Drugs Others , by Region USD Million (2018-2023)
  • Table 6. Anti-Aging Drugs: by Therapy(USD Million)
  • Table 7. Anti-Aging Drugs Homeopathic , by Region USD Million (2018-2023)
  • Table 8. Anti-Aging Drugs Allopathic , by Region USD Million (2018-2023)
  • Table 9. South America Anti-Aging Drugs, by Country USD Million (2018-2023)
  • Table 10. South America Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 11. South America Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 12. South America Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 13. Brazil Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 14. Brazil Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 15. Brazil Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 16. Argentina Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 17. Argentina Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 18. Argentina Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 19. Rest of South America Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 20. Rest of South America Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 21. Rest of South America Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 22. Asia Pacific Anti-Aging Drugs, by Country USD Million (2018-2023)
  • Table 23. Asia Pacific Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 24. Asia Pacific Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 25. Asia Pacific Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 26. China Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 27. China Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 28. China Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 29. Japan Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 30. Japan Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 31. Japan Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 32. India Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 33. India Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 34. India Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 35. South Korea Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 36. South Korea Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 37. South Korea Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 38. Taiwan Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 39. Taiwan Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 40. Taiwan Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 41. Australia Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 42. Australia Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 43. Australia Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 44. Rest of Asia-Pacific Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 45. Rest of Asia-Pacific Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 46. Rest of Asia-Pacific Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 47. Europe Anti-Aging Drugs, by Country USD Million (2018-2023)
  • Table 48. Europe Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 49. Europe Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 50. Europe Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 51. Germany Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 52. Germany Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 53. Germany Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 54. France Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 55. France Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 56. France Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 57. Italy Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 58. Italy Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 59. Italy Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 60. United Kingdom Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 61. United Kingdom Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 62. United Kingdom Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 63. Netherlands Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 64. Netherlands Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 65. Netherlands Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 66. Rest of Europe Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 67. Rest of Europe Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 68. Rest of Europe Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 69. MEA Anti-Aging Drugs, by Country USD Million (2018-2023)
  • Table 70. MEA Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 71. MEA Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 72. MEA Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 73. Middle East Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 74. Middle East Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 75. Middle East Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 76. Africa Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 77. Africa Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 78. Africa Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 79. North America Anti-Aging Drugs, by Country USD Million (2018-2023)
  • Table 80. North America Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 81. North America Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 82. North America Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 83. United States Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 84. United States Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 85. United States Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 86. Canada Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 87. Canada Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 88. Canada Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 89. Mexico Anti-Aging Drugs, by Application USD Million (2018-2023)
  • Table 90. Mexico Anti-Aging Drugs, by Therapy USD Million (2018-2023)
  • Table 91. Mexico Anti-Aging Drugs, by Drug Class USD Million (2018-2023)
  • Table 92. Anti-Aging Drugs Sales: by Application(K Tons)
  • Table 93. Anti-Aging Drugs Sales Skin and Hair , by Region K Tons (2018-2023)
  • Table 94. Anti-Aging Drugs Sales Skeletal and Muscles , by Region K Tons (2018-2023)
  • Table 95. Anti-Aging Drugs Sales Age Related Disorders , by Region K Tons (2018-2023)
  • Table 96. Anti-Aging Drugs Sales Others , by Region K Tons (2018-2023)
  • Table 97. Anti-Aging Drugs Sales: by Therapy(K Tons)
  • Table 98. Anti-Aging Drugs Sales Homeopathic , by Region K Tons (2018-2023)
  • Table 99. Anti-Aging Drugs Sales Allopathic , by Region K Tons (2018-2023)
  • Table 100. South America Anti-Aging Drugs Sales, by Country K Tons (2018-2023)
  • Table 101. South America Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 102. South America Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 103. South America Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 104. Brazil Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 105. Brazil Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 106. Brazil Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 107. Argentina Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 108. Argentina Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 109. Argentina Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 110. Rest of South America Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 111. Rest of South America Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 112. Rest of South America Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 113. Asia Pacific Anti-Aging Drugs Sales, by Country K Tons (2018-2023)
  • Table 114. Asia Pacific Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 115. Asia Pacific Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 116. Asia Pacific Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 117. China Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 118. China Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 119. China Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 120. Japan Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 121. Japan Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 122. Japan Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 123. India Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 124. India Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 125. India Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 126. South Korea Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 127. South Korea Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 128. South Korea Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 129. Taiwan Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 130. Taiwan Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 131. Taiwan Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 132. Australia Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 133. Australia Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 134. Australia Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 135. Rest of Asia-Pacific Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 136. Rest of Asia-Pacific Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 137. Rest of Asia-Pacific Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 138. Europe Anti-Aging Drugs Sales, by Country K Tons (2018-2023)
  • Table 139. Europe Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 140. Europe Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 141. Europe Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 142. Germany Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 143. Germany Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 144. Germany Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 145. France Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 146. France Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 147. France Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 148. Italy Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 149. Italy Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 150. Italy Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 151. United Kingdom Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 152. United Kingdom Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 153. United Kingdom Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 154. Netherlands Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 155. Netherlands Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 156. Netherlands Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 157. Rest of Europe Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 158. Rest of Europe Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 159. Rest of Europe Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 160. MEA Anti-Aging Drugs Sales, by Country K Tons (2018-2023)
  • Table 161. MEA Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 162. MEA Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 163. MEA Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 164. Middle East Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 165. Middle East Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 166. Middle East Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 167. Africa Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 168. Africa Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 169. Africa Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 170. North America Anti-Aging Drugs Sales, by Country K Tons (2018-2023)
  • Table 171. North America Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 172. North America Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 173. North America Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 174. United States Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 175. United States Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 176. United States Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 177. Canada Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 178. Canada Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 179. Canada Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 180. Mexico Anti-Aging Drugs Sales, by Application K Tons (2018-2023)
  • Table 181. Mexico Anti-Aging Drugs Sales, by Therapy K Tons (2018-2023)
  • Table 182. Mexico Anti-Aging Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 183. Company Basic Information, Sales Area and Its Competitors
  • Table 184. Company Basic Information, Sales Area and Its Competitors
  • Table 185. Company Basic Information, Sales Area and Its Competitors
  • Table 186. Company Basic Information, Sales Area and Its Competitors
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Anti-Aging Drugs: by Application(USD Million)
  • Table 194. Anti-Aging Drugs Skin and Hair , by Region USD Million (2025-2030)
  • Table 195. Anti-Aging Drugs Skeletal and Muscles , by Region USD Million (2025-2030)
  • Table 196. Anti-Aging Drugs Age Related Disorders , by Region USD Million (2025-2030)
  • Table 197. Anti-Aging Drugs Others , by Region USD Million (2025-2030)
  • Table 198. Anti-Aging Drugs: by Therapy(USD Million)
  • Table 199. Anti-Aging Drugs Homeopathic , by Region USD Million (2025-2030)
  • Table 200. Anti-Aging Drugs Allopathic , by Region USD Million (2025-2030)
  • Table 201. South America Anti-Aging Drugs, by Country USD Million (2025-2030)
  • Table 202. South America Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 203. South America Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 204. South America Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 205. Brazil Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 206. Brazil Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 207. Brazil Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 208. Argentina Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 209. Argentina Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 210. Argentina Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 211. Rest of South America Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 212. Rest of South America Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 213. Rest of South America Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 214. Asia Pacific Anti-Aging Drugs, by Country USD Million (2025-2030)
  • Table 215. Asia Pacific Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 216. Asia Pacific Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 217. Asia Pacific Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 218. China Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 219. China Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 220. China Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 221. Japan Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 222. Japan Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 223. Japan Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 224. India Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 225. India Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 226. India Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 227. South Korea Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 228. South Korea Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 229. South Korea Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 230. Taiwan Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 231. Taiwan Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 232. Taiwan Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 233. Australia Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 234. Australia Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 235. Australia Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 236. Rest of Asia-Pacific Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 237. Rest of Asia-Pacific Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 238. Rest of Asia-Pacific Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 239. Europe Anti-Aging Drugs, by Country USD Million (2025-2030)
  • Table 240. Europe Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 241. Europe Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 242. Europe Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 243. Germany Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 244. Germany Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 245. Germany Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 246. France Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 247. France Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 248. France Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 249. Italy Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 250. Italy Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 251. Italy Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 252. United Kingdom Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 253. United Kingdom Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 254. United Kingdom Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 255. Netherlands Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 256. Netherlands Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 257. Netherlands Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 258. Rest of Europe Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 259. Rest of Europe Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 260. Rest of Europe Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 261. MEA Anti-Aging Drugs, by Country USD Million (2025-2030)
  • Table 262. MEA Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 263. MEA Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 264. MEA Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 265. Middle East Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 266. Middle East Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 267. Middle East Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 268. Africa Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 269. Africa Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 270. Africa Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 271. North America Anti-Aging Drugs, by Country USD Million (2025-2030)
  • Table 272. North America Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 273. North America Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 274. North America Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 275. United States Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 276. United States Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 277. United States Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 278. Canada Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 279. Canada Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 280. Canada Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 281. Mexico Anti-Aging Drugs, by Application USD Million (2025-2030)
  • Table 282. Mexico Anti-Aging Drugs, by Therapy USD Million (2025-2030)
  • Table 283. Mexico Anti-Aging Drugs, by Drug Class USD Million (2025-2030)
  • Table 284. Anti-Aging Drugs Sales: by Application(K Tons)
  • Table 285. Anti-Aging Drugs Sales Skin and Hair , by Region K Tons (2025-2030)
  • Table 286. Anti-Aging Drugs Sales Skeletal and Muscles , by Region K Tons (2025-2030)
  • Table 287. Anti-Aging Drugs Sales Age Related Disorders , by Region K Tons (2025-2030)
  • Table 288. Anti-Aging Drugs Sales Others , by Region K Tons (2025-2030)
  • Table 289. Anti-Aging Drugs Sales: by Therapy(K Tons)
  • Table 290. Anti-Aging Drugs Sales Homeopathic , by Region K Tons (2025-2030)
  • Table 291. Anti-Aging Drugs Sales Allopathic , by Region K Tons (2025-2030)
  • Table 292. South America Anti-Aging Drugs Sales, by Country K Tons (2025-2030)
  • Table 293. South America Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 294. South America Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 295. South America Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 296. Brazil Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 297. Brazil Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 298. Brazil Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 299. Argentina Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 300. Argentina Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 301. Argentina Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 302. Rest of South America Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 303. Rest of South America Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 304. Rest of South America Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 305. Asia Pacific Anti-Aging Drugs Sales, by Country K Tons (2025-2030)
  • Table 306. Asia Pacific Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 307. Asia Pacific Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 308. Asia Pacific Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 309. China Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 310. China Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 311. China Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 312. Japan Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 313. Japan Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 314. Japan Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 315. India Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 316. India Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 317. India Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 318. South Korea Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 319. South Korea Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 320. South Korea Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 321. Taiwan Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 322. Taiwan Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 323. Taiwan Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 324. Australia Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 325. Australia Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 326. Australia Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 327. Rest of Asia-Pacific Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 328. Rest of Asia-Pacific Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 329. Rest of Asia-Pacific Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 330. Europe Anti-Aging Drugs Sales, by Country K Tons (2025-2030)
  • Table 331. Europe Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 332. Europe Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 333. Europe Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 334. Germany Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 335. Germany Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 336. Germany Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 337. France Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 338. France Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 339. France Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 340. Italy Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 341. Italy Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 342. Italy Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 343. United Kingdom Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 344. United Kingdom Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 345. United Kingdom Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 346. Netherlands Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 347. Netherlands Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 348. Netherlands Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 349. Rest of Europe Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 350. Rest of Europe Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 351. Rest of Europe Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 352. MEA Anti-Aging Drugs Sales, by Country K Tons (2025-2030)
  • Table 353. MEA Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 354. MEA Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 355. MEA Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 356. Middle East Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 357. Middle East Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 358. Middle East Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 359. Africa Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 360. Africa Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 361. Africa Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 362. North America Anti-Aging Drugs Sales, by Country K Tons (2025-2030)
  • Table 363. North America Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 364. North America Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 365. North America Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 366. United States Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 367. United States Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 368. United States Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 369. Canada Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 370. Canada Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 371. Canada Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 372. Mexico Anti-Aging Drugs Sales, by Application K Tons (2025-2030)
  • Table 373. Mexico Anti-Aging Drugs Sales, by Therapy K Tons (2025-2030)
  • Table 374. Mexico Anti-Aging Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 375. Research Programs/Design for This Report
  • Table 376. Key Data Information from Secondary Sources
  • Table 377. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anti-Aging Drugs: by Application USD Million (2018-2023)
  • Figure 5. Global Anti-Aging Drugs: by Therapy USD Million (2018-2023)
  • Figure 6. South America Anti-Aging Drugs Share (%), by Country
  • Figure 7. Asia Pacific Anti-Aging Drugs Share (%), by Country
  • Figure 8. Europe Anti-Aging Drugs Share (%), by Country
  • Figure 9. MEA Anti-Aging Drugs Share (%), by Country
  • Figure 10. North America Anti-Aging Drugs Share (%), by Country
  • Figure 11. Global Anti-Aging Drugs: by Application K Tons (2018-2023)
  • Figure 12. Global Anti-Aging Drugs: by Therapy K Tons (2018-2023)
  • Figure 13. South America Anti-Aging Drugs Share (%), by Country
  • Figure 14. Asia Pacific Anti-Aging Drugs Share (%), by Country
  • Figure 15. Europe Anti-Aging Drugs Share (%), by Country
  • Figure 16. MEA Anti-Aging Drugs Share (%), by Country
  • Figure 17. North America Anti-Aging Drugs Share (%), by Country
  • Figure 18. Global Anti-Aging Drugs share by Players 2023 (%)
  • Figure 19. Global Anti-Aging Drugs share by Players (Top 3) 2023(%)
  • Figure 20. Global Anti-Aging Drugs share by Players (Top 5) 2023(%)
  • Figure 21. BCG Matrix for key Companies
  • Figure 22. Nu Skin Enterprises (United States) Revenue, Net Income and Gross profit
  • Figure 23. Nu Skin Enterprises (United States) Revenue: by Geography 2023
  • Figure 24. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 26. BioTime Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. BioTime Inc. (United States) Revenue: by Geography 2023
  • Figure 28. ARK Skincare (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. ARK Skincare (United Kingdom) Revenue: by Geography 2023
  • Figure 30. Elysium Health Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Elysium Health Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Estee Lauder Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Estee Lauder Inc. (United States) Revenue: by Geography 2023
  • Figure 34. DermaFix (South Africa) Revenue, Net Income and Gross profit
  • Figure 35. DermaFix (South Africa) Revenue: by Geography 2023
  • Figure 36. Bayer Pharma AG (Germany) Revenue, Net Income and Gross profit
  • Figure 37. Bayer Pharma AG (Germany) Revenue: by Geography 2023
  • Figure 38. La Roche-Posay (United States) Revenue, Net Income and Gross profit
  • Figure 39. La Roche-Posay (United States) Revenue: by Geography 2023
  • Figure 40. L’Oreal SA (France) Revenue, Net Income and Gross profit
  • Figure 41. L’Oreal SA (France) Revenue: by Geography 2023
  • Figure 42. Global Anti-Aging Drugs: by Application USD Million (2025-2030)
  • Figure 43. Global Anti-Aging Drugs: by Therapy USD Million (2025-2030)
  • Figure 44. South America Anti-Aging Drugs Share (%), by Country
  • Figure 45. Asia Pacific Anti-Aging Drugs Share (%), by Country
  • Figure 46. Europe Anti-Aging Drugs Share (%), by Country
  • Figure 47. MEA Anti-Aging Drugs Share (%), by Country
  • Figure 48. North America Anti-Aging Drugs Share (%), by Country
  • Figure 49. Global Anti-Aging Drugs: by Application K Tons (2025-2030)
  • Figure 50. Global Anti-Aging Drugs: by Therapy K Tons (2025-2030)
  • Figure 51. South America Anti-Aging Drugs Share (%), by Country
  • Figure 52. Asia Pacific Anti-Aging Drugs Share (%), by Country
  • Figure 53. Europe Anti-Aging Drugs Share (%), by Country
  • Figure 54. MEA Anti-Aging Drugs Share (%), by Country
  • Figure 55. North America Anti-Aging Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Nu Skin Enterprises (United States)
  • Novartis AG (Switzerland)
  • BioTime Inc. (United States)
  • ARK Skincare (United Kingdom)
  • Elysium Health Inc. (United States)
  • Estee Lauder Inc. (United States)
  • DermaFix (South Africa)
  • Bayer Pharma AG (Germany)
  • La Roche-Posay (United States)
  • L’Oreal SA (France)
Select User Access Type

Key Highlights of Report


May 2024 206 Pages 89 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Anti-Aging Drugs Market Quantitative research analysis
Global Anti-Aging Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Anti-Aging Drugs Market are by end use application [Skin and Hair, Skeletal and Muscles, Age Related Disorders and Others].
The Anti-Aging Drugs Market is gaining popularity and expected to see strong valuation by 2030.
  • Rising awareness toward age related problems and increasing concerns about looks and appearance among people
  • Advancement in medical science and development of new anti-aging drugs
  • Growing aged population worldwide

Know More About Global Anti-Aging Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Animal Health Comprehensive Study by Type (Vaccines (Live Attenuated Vaccine, DNA Vaccines, Recombinant Vaccines and Inactivated Vaccines ), Feed Additives (Nutritional and Medicinal), Pharmaceutical...
$ 3750
Antibody Drugs Comprehensive Study by Type (Monoclonal Antibodies, Antibody-Drug Conjugates, Polyclonal Antibodies), Application (Central Nervous System (CNS) Disorders, Cancers, Autoimmune Disorders...
$ 3350
Capsule Shell Comprehensive Study by Type (Gelatin Capsule (Hard Gelatin Capsule, Soft Gelatin Capsule), Non-Gelatin Capsule), Application (Antibiotic Drugs, Vitamin and Dietary Supplements, Antacid ...
$ 3750
Diarrhea Drug Comprehensive Study by Type (Adult, Children), Application (Family, Hospital), Form (Syringe, Tablets), Dosage (10 mg, 15 mg, 20 mg, 30 mg) Players and Region - Global Market Outlook to...
$ 3500
Caspase 3 Comprehensive Study by Type (1G3-Cu, BaxM-159, Emricasan, IDN-7314, Others), Application (Liver Cirrhosis, Liver Failure, Pulmonary Fibrosis, Solid Tumor, Others) Players and Region - Globa...
$ 3400
Docetaxel Comprehensive Study by Type (40 mg/ml, 20 mg/ml, 10 mg/ml), Application (Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric Adenocarcinoma Cancer, Head and Neck Cancer), En...
$ 3650